These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19890962)

  • 1. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
    Flaherty KT
    Cancer; 2010 Jan; 116(1):4-7. PubMed ID: 19890962
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
    Reddy GK; Bukowski RM
    Clin Genitourin Cancer; 2006 Mar; 4(4):246-8. PubMed ID: 16729906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Verzoni E; Lanocita R; Procopio G
    Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
    [No Abstract]   [Full Text] [Related]  

  • 4. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
    Ravaud A; Digue L; Trufflandier N; Smith D
    Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
    [No Abstract]   [Full Text] [Related]  

  • 5. Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
    Ravaud A; Grossgoupil M
    Lancet Oncol; 2010 Apr; 11(4):307-8. PubMed ID: 20359658
    [No Abstract]   [Full Text] [Related]  

  • 6. [Targeted therapy - point blank or single shot].
    Rübben H
    Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy sequence for renal cell carcinoma--new aspects!].
    Miller K
    Aktuelle Urol; 2007 Jan; 38(1):59. PubMed ID: 17290332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
    Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
    J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    Di Lorenzo G; Autorino R
    J Urol; 2010 Feb; 183(2):824-5; author reply 825. PubMed ID: 20022057
    [No Abstract]   [Full Text] [Related]  

  • 10. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM; Plowman PN; Reznek R; Ball SA
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
    Morimoto H; Tsuzaka Y; Kaneko T; Matsushima H; Homma Y
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):2007-10. PubMed ID: 20948275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib-induced eruptive melanocytic lesions.
    Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
    Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
    Merseburger AS; Simon A; Waalkes S; Kuczyk MA
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1429-34. PubMed ID: 19828003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
    Gschwend JE
    Onkologie; 2010; 33 Suppl 1():10-1. PubMed ID: 20164670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.